Angel Physicians Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Orisdxorisdx.cominMay 2025
OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions.
BiotechDigital HealthMedical DevicesChicago, US
Harald Steltzer(Executive Officer, Director)inPatrick Conniff(Executive Officer)inEvgeny Izmchenko(Director)Nishant Agrawal(Director)in
Co-investorsHARPER COURT VENTURES
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.